Shares of ImmunoGen (IMGN) are up 68% after the company reported positive results in patients with Platinum-resistant ovarian cancer. These positive results were presented over this past weekend at the 2015 American Society For Clinical Oncology -- ASCO -- meeting. The trial findings come from a phase 1 trial and expansion phase 2 cohort that have recruited patients with FRa-positive platinum-resistant ovarian cancer.
Immunogen's mirvetuximab soravtansine is a drug compound that is being used in the study to help these patients with this form of platinum-resistant ovarian cancer. Prior to receiving Immunogen's drug, patients were given the standard care treatments for ovarian cancer known as taxane, as well as platinum therapy. Although 22 patients were established for efficacy only 17 were shown as part of the results at the ASCO meeting. This is because five patients had not completed treatment at the time of the abstract submission to the meeting.
The results showed that nine of the seventeen patients evaluated received an overall response rate of 53%. This means that on average 53% of these patients saw a reduction of the cancer to some degree. Eight patients achieved a partial response and one patients achieved a complete response. ImmunoGen will now prepare for a phase 2 trial with its drug compound to be used as a single-agent treatment in patients with FRa-positive platinum-resistant ovarian cancer.
Comments
Log in or sign up to join the conversation.